**Stony Brook University**

**Institutional Biosafety Committee (IBC)--Institutional Review Entity (IRE)**

**Dual Use Research of Concern (DURC)**

**Application**

**V.9.10.15**

**IRBNet #:**

**Principal Investigator’s Name:**

**Project Title:**

**Date:**

**Funding:** [ ]  Seeking funding [ ]  Funded [ ]  Internally Funded:

Agency:

Project-Task-Award #:

**1. Check all Agents or Toxins that are Involved in the Research:**

*Strains considered to be ‘attenuated’ and appearing on the Select Agent and Toxins Exclusions list:* [*http://www.selectagents.gov/SelectAgentsandToxinsExclusions.html*](http://www.selectagents.gov/SelectAgentsandToxinsExclusions.html) *do not need to be listed on this form as long as your project does not propose any manipulation that restores or enhances its virulence or toxic activity.*

[ ]  Avian influenza virus (highly pathogenic)

[ ]  *Bacillus anthracis*

[ ]  Botulinum neurotoxin (in any quantity)

[ ]  *Burkholderia mallei*

[ ]  *Burkholderia pseudomallei*

[ ]  Ebola virus

[ ]  Foot-and-mouth disease virus

[ ]  *Francisella tularensis*

[ ]  Marburg virus

[ ]  Reconstructed 1918 influenza virus

[ ]  Rinderpest virus

[ ]  Toxin-producing strains of *Clostridium botulinum*

[ ]  Variola major virus

[ ]  Variola minor virus

[ ]  *Yersinia pestis*

If any of the strains checked above are considered to be ‘attenuated’, but your research involves restoring or enhancing virulence or toxic activity, please explain:

**2. Personnel Training in DURC**

One of the responsibilities of the principal investigator is to ensure that laboratory personnel under his/her supervision who are working with any of the agents listed in #1 above have received training and education on DURC. List all personnel involved in this research, and the dates of completion of DURC training (as required and specified by SBU’s Policy and Procedures on Dual Use Research of Concern.

|  |  |  |  |
| --- | --- | --- | --- |
| **Last Name** | **First Name** | **SBU Employee ID# (not SSN)** | **DURC Training Completion Date**  |
| PI:       |  |       |        |
|       |  |       |        |
|       |  |       |        |
|       |  |       |        |
|       |  |       |        |
|       |  |       |        |

**3. Does your research that involves one or more the agents or toxins above also produce, aim to produce, or is reasonably anticipated to produce the following effects:**

Enhances the harmful consequences of the agent or toxin

[ ]  YES--explain why:

[ ]  NO

Disrupts immunity of the effectiveness of an immunization against the agent or toxin without clinical and/or agricultural justification

[ ]  YES--explain why:

[ ]  NO

Confers to the agent or toxin resistance to clinically and/or agriculturally useful prophylactic or therapeutic interventions against that agent or toxin or facilitates their ability to evade detection methodologies

[ ]  YES--explain why:

[ ]  NO

Increases the stability, transmissibility, or the ability to disseminate the agent or toxin

[ ]  YES--explain why:

[ ]  NO

Alters the host range or tropism of the agent or toxin

[ ]  YES--explain why:

[ ]  NO

Enhances the susceptibility of a host population to the agent or toxin

[ ]  YES--explain why:

[ ]  NO

Generates or reconstitutes an eradicated or extinct listed agent or toxin

[ ]  YES--explain why:

[ ]  NO

**4. Describe the aim(s) of your research:**

**5. Describe the experimental manipulations that will be performed:**

**6. Describe the anticipated outcome of your research:**

**7. Explain why you think that your research does or does not constitute dual use research of concern:**

Your e-signature on the IRBNet package for this submission certifies that:

* the information you have provided in this application is accurate
* you will not commence with the activity until you receive response from the Institutional Biosafety Committee regarding outcome of review.
* You will comply with any requirements stipulated by the IBC as a result of their review (including conducting and communicating the research in accordance with the provisions of the risk mitigation plan, if the IBC determines that the research constitutes dual use research of concern).